Neuware -Colonic drug delivery has gained increased importance not just for the delivery of the drugs for the treatment of local diseases associated with the colon like Crohn�s diseases, ulcerative colitis, irritable bowl syndrome but also for the potential it holds for the systemic delivery of proteins and therapeutic peptides. Targeted drug delivery to the colon would therefore, ensure direct treatment at the disease site and, consequently, lower dosing and reducing systemic side effects. The most critical challenge in such drug delivery approach is to preserve the formulation during its passage through the stomach and about first six meters of small intestine. In the present investigations, two drugs mesalamine and budesonide was selected for ulcerative colitis in colon. An attempt was made to prepare formulations which could not release the drug into stomach for up to 2 h. which is residence time for it, also it could not release the drug into small intestine up to 3 h. which is residence time for it and could release the drug up to 24 h to 3 days which is residence time for colon. These attempts formulate the colon targeted controlled release dosage form for ulcerative colitis.Books on Demand GmbH, �berseering 33, 22297 Hamburg 288 pp. Englisch.

N� de ref. del art�culo 9783844394825

Contactar al vendedor

Denunciar este art�culo

Detalles bibliogr�ficos

T�tulo: Design and Evaluation of Colon Specific Drug Delivery System
Editor: LAP Lambert Academic Publishing Apr 2016
Fecha de publicaci�n: 2016
Idioma: Ingl�s
ISBN 10: 3844394826
ISBN 13: 9783844394825
Encuadernaci�n: Taschenbuch
Estado: Neu
Dimensiones: 220�mil�metros de ancho por 150 de alto por 18 de largo
Peso: 447 gramos

Acerca de

Sinopsis

Colonic drug delivery has gained increased importance not just for the delivery of the drugs for the treatment of local diseases associated with the colon like Crohn’s diseases, ulcerative colitis, irritable bowl syndrome but also for the potential it holds for the systemic delivery of proteins and therapeutic peptides. Targeted drug delivery to the colon would therefore, ensure direct treatment at the disease site and, consequently, lower dosing and reducing systemic side effects. The most critical challenge in such drug delivery approach is to preserve the formulation during its passage through the stomach and about first six meters of small intestine. In the present investigations, two drugs mesalamine and budesonide was selected for ulcerative colitis in colon. An attempt was made to prepare formulations which could not release the drug into stomach for up to 2 h. which is residence time for it, also it could not release the drug into small intestine up to 3 h. which is residence time for it and could release the drug up to 24 h to 3 days which is residence time for colon. These attempts formulate the colon targeted controlled release dosage form for ulcerative colitis.

Rese�a del editor

Colonic drug delivery has gained increased importance not just for the delivery of the drugs for the treatment of local diseases associated with the colon like Crohn's diseases, ulcerative colitis, irritable bowl syndrome but also for the potential it holds for the systemic delivery of proteins and therapeutic peptides. Targeted drug delivery to the colon would therefore, ensure direct treatment at the disease site and, consequently, lower dosing and reducing systemic side effects. The most critical challenge in such drug delivery approach is to preserve the formulation during its passage through the stomach and about first six meters of small intestine. In the present investigations, two drugs mesalamine and budesonide was selected for ulcerative colitis in colon. An attempt was made to prepare formulations which could not release the drug into stomach for up to 2 h. which is residence time for it, also it could not release the drug into small intestine up to 3 h. which is residence time for it and could release the drug up to 24 h to 3 days which is residence time for colon. These attempts formulate the colon targeted controlled release dosage form for ulcerative colitis.

"Sobre este t�tulo" puede pertenecer a otra edici�n de este libro.

Descripci�n de la librer�a

Impressum Thorsten Retsch Buchversand Mimpf2000 Ober�lschnitz 16 95517 Emtmannsberg Deutschland Telefon: 09209-2023188 Email: mimpf2000@online.de USt-ID-Nr.: DE 235096871 Wir f�hren gebrauchte B�cher aus allen Sparten der Literatur

Ver la p�gina web de la librer�a

Informaci�n empresarial del vendedor

buchversandmimpf2000
Germany

Condiciones de venta y env�o

Condiciones de venta

Widerrufsbelehrung/ Muster-Widerrufsformular/
Allgemeine Gesch�ftsbedingungen und Kundeninformationen/ Datenschutzerkl�rung

Widerrufsrecht f�r Verbraucher
(Verbraucher ist jede nat�rliche Person, die ein Rechtsgesch�ft zu Zwecken abschlie�t, die �berwiegend weder ihrer gewerblichen noch ihrer selbstst�ndigen beruflichen T�tigkeit zugerechnet werden k�nnen.)

Widerrufsbelehrung

Widerrufsrecht
Sie haben das Recht, binnen 14 Tagen ohne Angabe von Gr�nden diesen Vertrag zu widerrufen.
Die Widerrufsfr...

M�s informaci�n

Derecho a cancelaci�n

Condiciones de env�o

Soweit in der Artikelbeschreibung keine andere Frist angegeben ist, erfolgt die Lieferung der Ware innerhalb von 3-5 Werktagen nach Vertragsschluss, bei Vorauszahlung erst nach Eingang des vollst�ndigen Kaufpreises und der Versandkosten. Alle Preise inkl. MwSt.

Tarifas de env�o de Alemania a Estados Unidos de America

Tarifas de env�o de Alemania a Estados Unidos de America
Cantidad del pedido	De 60 a 60 d�as h�biles	De 60 a 60 d�as h�biles
Primer art�culo	EUR 60.00	EUR 75.00

Los plazos de entrega los establecen los vendedores y var�an seg�n el transportista y la ubicaci�n. Los pedidos que pasan por la aduana pueden sufrir retrasos y los compradores son responsables de los aranceles o tarifas asociadas. Los vendedores pueden ponerse en contacto con usted en relaci�n con cargos adicionales para cubrir cualquier aumento en los costes de env�o de los art�culos.

Informaci�n detallada sobre el vendedor